Women's HealthPhase 1NCT06213428
Effects of Probiotics on Synaptic Plasticity During the Menstrual Cycle
A Phase 1 study testing Progressive Perfect Probiotic in people with Women's Health and Brain Plasticity, run by McMaster University at 1 site in Canada.
Trial summary
Modulation of our gut microbiota through probiotics, can improve our emotional state, decrease pain sensitivity, improve cognitive processes, increase neurotransmitter levels and alter functional connectivity. In addition, probiotics regulate estrogen levels. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Women's Health, Brain Plasticity
- What is being tested?
- Progressive Perfect Probiotic
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteCanada
- Study dates
- Jan 2024to May 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- right handed, females between 18-35 years old with a regular menstrual cycle (approximately 26-30 days)
Who cannot join
- contradictions to TMS
- contradictions to probiotic
- Females who use hormone altering devices (i.e. oral contraceptives)
Trial locations and contacts
1 site in 1 country.
Faith C Adams, BSc contact
About this study
Official title: Investigating the Effects of Probiotics on Synaptic Plasticity in the Follicular and Luteal Phases of the Menstrual Cycle
Modulation of our gut microbiota through probiotics, can improve our emotional state, decrease pain sensitivity, improve cognitive processes, increase neurotransmitter levels and alter functional connectivity. In addition, probiotics regulate estrogen levels. Estrogen levels have been recognized to influence the gut microbiota, impact neural activity, memory, and cognition.
This study aims 1) to determine whether probiotics can increase the propensity for synaptic plasticity in females and 2) to determine if there are differences in the propensity for plasticity depending on the phase of the menstrual cycle.
Read the detailed description
The human gastrointestinal (GI) tract is comprised of trillions of bacterial strains. Recent work has focused on investigating the influence of the gut microbiota on the processing and function of our brain; this is known as the 'gut-brain axis'. Our gut microbiota can be altered through diet, antibiotics, prebiotics and probiotics (Hemarajata et al., 2013). Probiotics are live microorganisms, which when delivered in adequate amounts, can offer beneficial health outcomes to the host (Hill et al., 2014). Modulation of our gut microbiota through probiotics, can improve our emotional state (Bagga et al., 2018; Messaoudi et al., 2011; Tillisch et al., 2013), decrease pain sensitivity (Weizman et al., 2016), improve cognitive processes (Chung et al., 2014; Kim et al., 2020), increase neurotransmitter levels (Mittal et al., 2017) and alter functional connectivity (Rode et al., 2022; Bagga et al., 2019). In addition, probiotics regulate estrogen levels (Guo et al., 2016; Urbaniak et al., 2016).
Estrogen levels have been recognized to influence the gut microbiota. The gut produces β-glucuronidases which is the enzyme required to breakdown conjugated estrogen into its active form (Dabek et al., 2008; Ervin et al., 2019). Low β-glucuronidases production occur in the presence of diminished bacterial diversity levels in the gut. The consequence of the low β-glucuronidases is a reduction in active forms of estrogen (Siddiqui et al., 2022; Pugh et al., 2021; Kwa et al., 2016, Baker et al., 2017). Further, gastrointestinal symptoms increase during menstruation (Pugh et al., 2021). Last, irritable bowel syndrome is more prevalent in females, indicating a possible role of sex hormones in relation to the gut microbiome (Pugh et al., 2021).
Estrogen has been found to impact neural activity, memory, and cognition (Inghilleri et al., 2004; Luine 2014). EEG brain activity was collected from women in their follicular and luteal phase (Brotzner et al., 2014). When estrogen levels were highest, individual alpha frequency oscillations (IAF) were lowest (Brotzner et al., 2014), the latter is associated with reduced cognition and working memory (Li et al., 2023). In addition, estrogen was found to reduce the firing threshold in some neurons which can promote excitability in the cortex (Gregory et al., 2019). Conversely, high progesterone levels are known to increase GABA activity which reduces neural activity (Guennoun et al., 2015). Furthermore, a 5Hz repetitive transcranial magnetic stimulation (rTMS) protocol was delivered over the motor cortex during the early and late follicular phase (Inghilleri et al., 2004). Corticospinal activity was increased when estradiol levels were highest (Inghilleri et al., 2004) showing the association between estradiol and synaptic plasticity.
Collectively, the literature suggests that women may have a reduced capacity for synaptic plasticity during the luteal phase when estradiol levels are low. Introducing a probiotic will increase β-glucuronidases which leads to greater availability of circulating estrogen which should promote synaptic plasticity. It is hypothesized that increases in synaptic plasticity will occur in the follicular and luteal phase in the presence of probiotics. This study aims 1) to determine whether probiotics can increase the propensity for synaptic plasticity in females and 2) to determine if there are differences in the propensity for plasticity depending on the phase of the menstrual cycle.
Methods:
Participants will be randomized into Group A or Group B. Twenty participants will be in Group A and 20 participants will be in group B. If randomized to Group A, all visits will be conducted between day 6-9 (mid-follicular phase) when estradiol levels are highest. If randomized to Group B, all visits will be conducted during day 19-23 (mid-luteal phase) when progesterone levels are highest. This will be a randomized, crossover, double-masked study whereby participants will receive both real probiotic and placebo probiotic for 28 days. Assessments will be acquired during four visits (Before and after each intervention, separated by a 28 day washout). The McMaster University Medical Centre (MUMC) pharmacy will be responsible for the preparation of the blinded probiotic kits and randomization schedule. The probiotic used will be a commercially available product called Progressive Perfect Probiotic (https://www.progressivenutritional.com/products/perfect-probiotic-120-billion).
The following dependent measures will be used: Active motor threshold, Resting motor threshold, short interval intracortical inhibition, motor evoked potentials.
These measures will be taken before and after a synaptic plasticity inducing protocol
To assess synaptic plasticity, repetitive TMS will be performed using a 70mm inner diameter figure-of-eight coil with a Magstim Super Rapid2 Plus Stimulator (Magstim, Whitland, UK). Biphasic magnetic pulses will be delivered over the primary motor area of the dominant hemisphere to find the optimal position for eliciting a MEP in the contralateral APB muscle. Intermittent theta burst stimulation (iTBS) protocol will be delivered using biphasic pulses in burst of three pulses delivered in 6Hz trains that will last 2s, this will be followed by 8s with no pulse delivered. iTBS will be repeated for a total of 612 pulses at 80% of AMT (Fassett et al., 2017).
- Conditions
- Women's Health, Brain Plasticity
- Being tested
- Progressive Perfect Probiotic, Placebo
- Keywords
- Probiotic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Progressive Perfect ProbioticBiological
Participants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing.
PlaceboOther
Participants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing.
| Study group | Role | What they receive |
|---|---|---|
| Active: Probiotic | Active comparator | Progressive Perfect Probiotic 120 Billion CFU containing the following strains will be used:
Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium animalis subsp.lactis, Bifidobacterium breve, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus reuteri, Bifidobacterium bifidum, Bifidobacterium longum subsp. Longum.
Participants will be required to take one capsule a day, for 28 days. Receives: Biological: Progressive Perfect Probiotic |
| Placebo Probiotic | Placebo comparator | A placebo that is identical in capsule size and colour to the active probiotic capsule will be used. This will ensure participants and experimenters are masked during each intervention period. Participants will be required to take one capsule a day for 28 days. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change Motor Evoked Potentials (MEPs)
Change in MEPs using TMS
Measured: Immediately before intervention, immediately following 4 week intervention
Secondary outcomes (1)
Short Interval intracortical inhibition (SICI)
Changes in SICI Using TMS
Measured: Immediately before intervention, immediately following 4 week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jan 2024
- Study startJan 2024 (estimated)
- Primary completionMay 2025 (estimated)
- Study completionMay 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Women's HealthStudies of the same condition, open and under way.
- More trials run by McMaster UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- McMaster University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aimee Nelson, McMaster University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06213428
- Sponsor's protocol ID
- 16602
- Status last verified
- Jan 2024
- First submitted
- 26 Dec 2023
- Last updated
- 19 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the Effects of Probiotics on Synaptic Plasticity in the Follicular and Luteal Phases of the Menstrual Cycle
- ClinicalTrials.gov ID
- NCT06213428
- Acronym / sponsor ID
- 16602
- Conditions
- Women's Health, Brain Plasticity
- Keywords
- Probiotic
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- McMaster UniversityUniversity, hospital or other
- Study start
- Jan 2024 (estimated)
- Primary completion
- May 2025 (estimated)
- Study completion
- May 2025 (estimated)
- First posted
- 19 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Modulation of our gut microbiota through probiotics, can improve our emotional state, decrease pain sensitivity, improve cognitive processes, increase neurotransmitter levels and alter functional connectivity. In addition, probiotics regulate estrogen levels. Estrogen levels have been recognized to influence the gut microbiota, impact neural activity, memory, and cognition.
This study aims 1) to determine whether probiotics can increase the propensity for synaptic plasticity in females and 2) to determine if there are differences in the propensity for plasticity depending on the phase of the menstrual cycle.
Detailed description
The human gastrointestinal (GI) tract is comprised of trillions of bacterial strains. Recent work has focused on investigating the influence of the gut microbiota on the processing and function of our brain; this is known as the 'gut-brain axis'. Our gut microbiota can be altered through diet, antibiotics, prebiotics and probiotics (Hemarajata et al., 2013). Probiotics are live microorganisms, which when delivered in adequate amounts, can offer beneficial health outcomes to the host (Hill et al., 2014). Modulation of our gut microbiota through probiotics, can improve our emotional state (Bagga et al., 2018; Messaoudi et al., 2011; Tillisch et al., 2013), decrease pain sensitivity (Weizman et al., 2016), improve cognitive processes (Chung et al., 2014; Kim et al., 2020), increase neurotransmitter levels (Mittal et al., 2017) and alter functional connectivity (Rode et al., 2022; Bagga et al., 2019). In addition, probiotics regulate estrogen levels (Guo et al., 2016; Urbaniak et al., 2016).
Estrogen levels have been recognized to influence the gut microbiota. The gut produces β-glucuronidases which is the enzyme required to breakdown conjugated estrogen into its active form (Dabek et al., 2008; Ervin et al., 2019). Low β-glucuronidases production occur in the presence of diminished bacterial diversity levels in the gut. The consequence of the low β-glucuronidases is a reduction in active forms of estrogen (Siddiqui et al., 2022; Pugh et al., 2021; Kwa et al., 2016, Baker et al., 2017). Further, gastrointestinal symptoms increase during menstruation (Pugh et al., 2021). Last, irritable bowel syndrome is more prevalent in females, indicating a possible role of sex hormones in relation to the gut microbiome (Pugh et al., 2021).
Estrogen has been found to impact neural activity, memory, and cognition (Inghilleri et al., 2004; Luine 2014). EEG brain activity was collected from women in their follicular and luteal phase (Brotzner et al., 2014). When estrogen levels were highest, individual alpha frequency oscillations (IAF) were lowest (Brotzner et al., 2014), the latter is associated with reduced cognition and working memory (Li et al., 2023). In addition, estrogen was found to reduce the firing threshold in some neurons which can promote excitability in the cortex (Gregory et al., 2019). Conversely, high progesterone levels are known to increase GABA activity which reduces neural activity (Guennoun et al., 2015). Furthermore, a 5Hz repetitive transcranial magnetic stimulation (rTMS) protocol was delivered over the motor cortex during the early and late follicular phase (Inghilleri et al., 2004). Corticospinal activity was increased when estradiol levels were highest (Inghilleri et al., 2004) showing the association between estradiol and synaptic plasticity.
Collectively, the literature suggests that women may have a reduced capacity for synaptic plasticity during the luteal phase when estradiol levels are low. Introducing a probiotic will increase β-glucuronidases which leads to greater availability of circulating estrogen which should promote synaptic plasticity. It is hypothesized that increases in synaptic plasticity will occur in the follicular and luteal phase in the presence of probiotics. This study aims 1) to determine whether probiotics can increase the propensity for synaptic plasticity in females and 2) to determine if there are differences in the propensity for plasticity depending on the phase of the menstrual cycle.
Methods:
Participants will be randomized into Group A or Group B. Twenty participants will be in Group A and 20 participants will be in group B. If randomized to Group A, all visits will be conducted between day 6-9 (mid-follicular phase) when estradiol levels are highest. If randomized to Group B, all visits will be conducted during day 19-23 (mid-luteal phase) when progesterone levels are highest. This will be a randomized, crossover, double-masked study whereby participants will receive both real probiotic and placebo probiotic for 28 days. Assessments will be acquired during four visits (Before and after each intervention, separated by a 28 day washout). The McMaster University Medical Centre (MUMC) pharmacy will be responsible for the preparation of the blinded probiotic kits and randomization schedule. The probiotic used will be a commercially available product called Progressive Perfect Probiotic (https://www.progressivenutritional.com/products/perfect-probiotic-120-billion).
The following dependent measures will be used: Active motor threshold, Resting motor threshold, short interval intracortical inhibition, motor evoked potentials.
These measures will be taken before and after a synaptic plasticity inducing protocol
To assess synaptic plasticity, repetitive TMS will be performed using a 70mm inner diameter figure-of-eight coil with a Magstim Super Rapid2 Plus Stimulator (Magstim, Whitland, UK). Biphasic magnetic pulses will be delivered over the primary motor area of the dominant hemisphere to find the optimal position for eliciting a MEP in the contralateral APB muscle. Intermittent theta burst stimulation (iTBS) protocol will be delivered using biphasic pulses in burst of three pulses delivered in 6Hz trains that will last 2s, this will be followed by 8s with no pulse delivered. iTBS will be repeated for a total of 612 pulses at 80% of AMT (Fassett et al., 2017).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active: Probiotic | Active comparator | Biological: Progressive Perfect ProbioticProgressive Perfect Probiotic 120 Billion CFU containing the following strains will be used: Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium animalis subsp.lactis, Bifidobacterium breve, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus reuteri, Bifidobacterium bifidum, Bifidobacterium longum subsp. Longum. Participants will be required to take one capsule a day, for 28 days. |
| Placebo Probiotic | Placebo comparator | Other: PlaceboA placebo that is identical in capsule size and colour to the active probiotic capsule will be used. This will ensure participants and experimenters are masked during each intervention period. Participants will be required to take one capsule a day for 28 days. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- right handed, females between 18-35 years old with a regular menstrual cycle (approximately 26-30 days)
Key exclusion criteria (3 listed)
- contradictions to TMS
- contradictions to probiotic
- Females who use hormone altering devices (i.e. oral contraceptives)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Progressive Perfect ProbioticParticipants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing. | Biological | Active: Probiotic |
| PlaceboParticipants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing. | Other | Placebo Probiotic |
Primary outcome
Change Motor Evoked Potentials (MEPs)
Time frame: Immediately before intervention, immediately following 4 week intervention
Change in MEPs using TMS
1 secondary outcome
Short Interval intracortical inhibition (SICI)
Time frame: Immediately before intervention, immediately following 4 week intervention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jan 2024.
Related trials for Women's Health
Not yet recruiting
Radiofrequency and Pelvic Floor Exercise for Primary Dysmenorrhea
Primary Dysmenorrhea
RecruitingObservational study
Lived Experiences of Women Diagnosed With HPV Infection
Human Papillomavirus Infection
Recruiting
Restoring Emotional Needs With Exogenous Ketones for Women With Postpartum Depression
Postpartum Depression (PPD)
RecruitingPhase 2/3
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Menopause, Menopause Hot Flashes
Recruiting
Dance-Based Exercise Versus Clinical Pilates in Women With Overweight or Obesity
Overweight, Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Faith C Adams, BSc contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Progressive Perfect Probiotic in people with Women's Health and Brain Plasticity, run by McMaster University at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Aimee J Nelson, PhD (9055259140 ext. 28053, nelsonaj@mcmaster.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change Motor Evoked Potentials (MEPs) (time frame: Immediately before intervention, immediately following 4 week intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jan 2024.